International Ophthalmology

, Volume 30, Issue 4, pp 429–434 | Cite as

Intra-ocular expression of vascular endothelial growth factor (VEGF) and pigment epithelial-derived factor (PEDF) in a case of Eales’ disease by immunohistochemical analysis: a case report

  • Aditya Verma
  • Jyotirmay Biswas
  • Selvi Radhakrishnan
  • Angayarkanni Narayanasamy
Case Report


We report a immunohistochemical study of expression of VEGF and PEDF in Eales’ disease. An enucleated eye from a patient with Eales’ disease and an age and sex-matched donor eyeball were subjected to immunohistochemical and histopathological analysis to study the expression of VEGF and PEDF in the retinal region. Strong positive anti-VEGF immunostaining was found around the vessel walls in the retina in the eyeball from the Eales’ disease patient compared with the donor control, from which it was almost absent. PEDF staining was detected in the normal donor eyeball retinal layers surrounding the blood vessels, and the photoreceptor and ganglion cell layer, whereas in the eyeball from Eales’ disease patient PEDF staining was restricted to the surrounding blood vessels. The strong expression of VEGF in eyes with Eales’ disease as opposed to weak expression of PEDF indicates the propensity of the disease to show neovascularization and recurrent hemorrhages.


Eales’ disease Hypoxia Immunohistochemistry Pigment-derived growth factor (PEDF) Vascular endothelial growth factor (VEGF) Vasopermeability factor 



We are extremely grateful for the antibody gifted by Dr Tombaran Tink and Dr Barnstable, Department of Ophthalmology and Visual science, Yale University, USA. This work is supported by the Vision Research Foundation, Chennai, India.


  1. 1.
    Daxer A (1993) Characterisation of the neovascularization process in diabetic retinopathy by means of fractal geometry: diagnostic implications. Graefes Arch Clin Exp Ophthalmol 231:681–686CrossRefPubMedGoogle Scholar
  2. 2.
    Hvarfner C, Hillarp A, Larsson J (2003) Influence of factor V Leiden on the development of neovascularization secondary to central retinal vein occlusion. Br J Ophthalmol 87:305–306CrossRefPubMedGoogle Scholar
  3. 3.
    Zhang S, Leske DA, Holmes JM (2000) Neovascularization grading methods in a rat model of retinopathy of prematurity. Invest Ophthalmol Vis Sci 41:887–891PubMedGoogle Scholar
  4. 4.
    Ornitz DM, Itoh N (2001) Fibroblast growth factors. Genome Biol 2:1–12CrossRefGoogle Scholar
  5. 5.
    Thurston G (2003) Role of angiopoietins and tie receptor tyrosine kinases in angiogenesis and lymphangiogenesis. Cell Tissue Res 314:61–68CrossRefPubMedGoogle Scholar
  6. 6.
    Haas TL, Milkiewicz M, Davis SJ, Zhou AL, Egginton S, Brown MD, Madri JA, Hudlicka O (2009) Matrix metalloproteinase activity is required for activity-induced angiogenesis in rat skeletal muscle. Am J Physiol Heart Circ Physiol 279:H1540–H1547Google Scholar
  7. 7.
    Blobe GC, Schiemann WP, Lodish HF (2000) Role of transforming growth factor beta in human disease. N Engl J Med 342:1350–1358CrossRefPubMedGoogle Scholar
  8. 8.
    Aiello LP, Avery RL, Arrigg PG, Keyt BA, Jampel HD, Shah ST, Pasquale LR, Thieme H, Iwamoto MA, Park JE et al (1994) Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 331:1480–1487CrossRefPubMedGoogle Scholar
  9. 9.
    Okamoto N, Tobe T, Hackett S, Ozaki H, Vinores M, LaRochelle W, Zack D, Campochiaro P (1997) Transgenic mice with increased expression of vascular endothelial growth factor in the retina: a new model of intraretinal and subretinal neovascularization. Am J Pathol 151:281–291PubMedGoogle Scholar
  10. 10.
    Ashton N (1957) Retinal vascularization in health and disease. Am J Ophthalmol 44:7–24PubMedGoogle Scholar
  11. 11.
    Takahashi H, Tamaki Y, Ishii N, Oikawa N, Mizuguchi E, Francis JH, Inoue Y, Iriyama A, Obata R, Yanagi Y (2008) Identification of a novel vascular endothelial growth factor receptor 2 inhibitor and its effect for choroidal neovascularization in vivo. Curr Eye Res 33:1002–1010CrossRefPubMedGoogle Scholar
  12. 12.
    Patel JI, Tombran-Tink J, Hykin PG, Gregor ZJ, Cree IA (2006) Vitreous and aqueous concentrations of proangiogenic, antiangiogenic factors and other cytokines in diabetic retinopathy patients with macular edema: Implications for structural differences in macular profiles. Exp Eye Res 82:798–806CrossRefPubMedGoogle Scholar
  13. 13.
    Yokoi M, Yamagishi S, Saito A, Yoshida Y, Matsui T, Saito W, Hirose S, Ohgami K, Kase M, Ohno S (2007) Positive association of pigment epithelium-derived factor (PEDF) with total anti-oxidant capacity in the vitreous fluid of patients with proliferative diabetic retinopathy. Br J Ophthalmol 91:885–887CrossRefPubMedGoogle Scholar
  14. 14.
    Rajesh M, Sulochana KN, Ramakrishnan S, Biswas J, Manoharan PT (2004) Iron chelation abrogates excessive formation of hydroxyl radicals and lipid peroxidation products in monocytes of patients’ with Eales’ disease: direct evidence using Electron Spin Resonance Spectroscopy. Curr Eye Res 28:399–407CrossRefPubMedGoogle Scholar
  15. 15.
    Bhooma V, Sulochana KN, Biswas J, Ramakrishnan S (1997) Eales’ disease: accumulation of reactive oxygen intermediates and lipid peroxide and decrease of anti-oxidants causing inflammation, neovascularization and retinal damage. Curr Eye Res 16:91–95CrossRefPubMedGoogle Scholar
  16. 16.
    Perentes Y, Chan CC, Bovey E, Uffer S, Herbort CP (2002) Massive vascular endothelium growth factor (VEGF) expression in Eales’ disease. Klin Monatsbl Augenheilkd 219:311–314CrossRefPubMedGoogle Scholar
  17. 17.
    Breier G, Albrecht U, Sterrer S, Risau W (1992) Expression of vascular endothelial growth factor during embryonic angiogenesis and endothelial cell differentiation. Development 114:521–532PubMedGoogle Scholar
  18. 18.
    Leung DW, Cachianes G, Kunang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309CrossRefPubMedGoogle Scholar
  19. 19.
    Shweiki D, Itin A, Soffer D et al (1992) Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 359:843–845CrossRefPubMedGoogle Scholar
  20. 20.
    Shima D, Gougos A, Miller J et al (1996) Cloning and mRNA expression of VEGF in ischemic retinas of Macacca fascicularis. Invest Ophthalmol Vis Sci 37:1334–1340PubMedGoogle Scholar
  21. 21.
    Schlingemann RO, van Hinsbergh VW (1997) Role of vascular permeability factor/vascular endothelial growth factor in eye disease. Br J Ophthalmol 81:501–512CrossRefPubMedGoogle Scholar
  22. 22.
    Dawson DW, Volpert OV, Gillis P et al (1999) Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 285:245–248CrossRefPubMedGoogle Scholar
  23. 23.
    Stellmach V, Crawford SE, Zhou W et al (2001) Prevention of ischemia-induced retinopathy by the natural ocular antiangiogenic agent pigment epithelium-derived factor. Proc Natl Acad Soc USA 98:2593–2597CrossRefGoogle Scholar
  24. 24.
    Kumar A, Sinha S (2007) Rapid regression of disc and retinal neovascularization in a case of Eales’ disease after intravitreal bevacizumab. Can J Ophthalmol 42:335–336CrossRefPubMedGoogle Scholar
  25. 25.
    Murugeswari P, Shukla D, Rajendran A, Kim R, Namperumalsamy P, Muthukarruppan V (2008) Proinflammatory cytokines and angiogenic and anti-angiogenic cytokines in vitreous of patients with proliferative diabetic retinopathy and Eales’ disease. Retina 28:817–824CrossRefPubMedGoogle Scholar
  26. 26.
    Angayarkanni N, Selvi R, Pukraj R, Biswas J, Bhavesh SJ, Tombran-Tink J, Barnstable CJ (2009) Ratio of the vitreous vascular endothelial growth factor and pigment epithelial-derived factor in Eales’ disease. J Ocular Biol Dis Inform 2:20–28CrossRefGoogle Scholar
  27. 27.
    Kim I, Ryan MA, Rohan R, Amano S, Agular S, Miller JW, Adamis AP (1999) Constitutive expression of VEGF, VEGFR1 and VEGFR2 in normal eyes. Invest Ophthalmol Vis Sci 40:2115–2121PubMedGoogle Scholar
  28. 28.
    Witmer AN, Blaauwgeers HG, Weich HA, Alitalo K, Vrensen GFJM, Schlingemann RO (2002) Altered expression patterns of VEGF receptors in human diabetic retina and in experimental VEGF induced retinopathy in monkey. Invest Ophthalmol Vis Sci 43:849–857PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2010

Authors and Affiliations

  • Aditya Verma
    • 1
  • Jyotirmay Biswas
    • 1
  • Selvi Radhakrishnan
    • 2
  • Angayarkanni Narayanasamy
    • 2
  1. 1.Department of Ocular PathologyMedical Research Foundation, Sankara NethralayaChennaiIndia
  2. 2.Department of BiochemistryMedical Research Foundation, Sankara NethralayaChennaiIndia

Personalised recommendations